MOA Open Access, Inc. (d/b/a VisionLOCK), an innovative specialty service provider for cataract surgeons, is driving its growth strategies with the help of FORT Capital Resources. Through its VisionLOCK Adjustment Centers, the company is accelerating the adoption of the most advanced technology in cataract surgery today – the RxSight Light Adjustable Lens® (LAL) – by providing the postoperative refractive adjustments required for the lens in order to expand access for surgeons and patients alike. The LAL is fueling growth in the premium lens segment for patients seeking the best visual outcomes. Revenue projections for LAL are further accelerated by demographic trends driving demand for cataract surgery, already the most ubiquitous surgery in the US and projected to reach 6 million by 2030.
MOA Open Access (MOA-OA) currently has 8 VisionLOCK Adjustment Centers in the Northeast. To keep pace with its expansion and growth plans, the company turned to FORT Capital Resources, renowned for providing finance solutions that align with their clients' goals, to provide the necessary support to drive MOA-OA’s objectives forward. The collaboration between MOA-OA, FORT Capital Resources, and their leading medical advisors highlights the power of strategic partnerships in creating value and success for all involved. With FORT’s expertise, MOA-OA is now poised to continue rapid growth in its operations and deliver even more value to its patients and surgeon partners.
“The LAL is the most significant advancement in cataract surgery today and now MOA Open Access is making this innovative technology more readily available, enabling surgeons to help their patients achieve superior visual outcomes,” Eric Donnenfeld, MD, Partner, OCLI Vision, Clinical Professor, NYU, and MOA Open Access Board Member.
About MOA Open Access, Inc.
MOA Open Access, Inc. is developing a national network of VisionLOCK Adjustment Centers utilizing the Light Adjustable Lens® technology commercialized by RxSight, a publicly held company. The Light Adjustable Lens (LAL™/LAL+™) is the world’s first and only adjustable intraocular lens (IOL) that is customized to a patient's unique visual needs after cataract surgery. The Company places RxSight's Light Delivery Devices (LDDs) in its VisionLOCK centers to provide the post-surgical adjustments for the LAL. The Company will expand access to this premium cataract surgery option by eliminating the cost of the device to surgeons, providing the resources to perform the post-surgical adjustments, and building a referral network of cataract surgeons to work with each VisionLOCK adjustment center.